Maetani Iruru, Ukita Takeo, Tada Tomoko, Shigoka Hiroaki, Omuta Shigefumi, Endo Takuro
Department of Internal Medicine, Division of Gastroenterology, Toho University Ohashi Medical Center, Tokyo, Japan.
Gastrointest Endosc. 2009 Apr;69(4):806-12. doi: 10.1016/j.gie.2008.06.009. Epub 2009 Jan 10.
Self-expandable metallic stents (SEMSs) are widely used for palliation of malignant gastric outlet obstruction (GOO). A common complication of their use, however, is stent obstruction caused by tumor ingrowth or hyperplasia. The covered SEMS was designed to prevent these problems.
We compared the performance of uncovered and covered SEMSs in patients with GOO.
A retrospective study, single center.
A tertiary-referral center.
Sixty patients with symptomatic malignant GOO.
All patients received an uncovered or covered knitted nitinol stent by using the over-the-wire placement procedure.
Comparison of the clinical outcome, complications, and the reintervention rate between uncovered and covered stents.
Thirty-one patients (mean [+/-SEM] age 72.2 +/- 2.1 years; 16 men) received uncovered SEMSs, and 29 (mean [+/-SEM] age 70.6 +/- 1.7 years; 17 men) received covered SEMSs. The technical success rate was 100% in both groups. No difference in clinical success was seen (90.3% uncovered group vs 86.2% covered group). Regarding early complications (<1 week), one mild case of pancreatitis from the stent covering the papilla occurred in each group. Late complications included reobstruction, migration, bleeding, stent fracture, and perforation. The occurrence of reobstruction did not differ between the 2 groups (3.2% uncovered group vs 10.3% covered group). No difference in migration (0% uncovered group vs 6.9% covered group) was seen. The uncovered group required less frequent reinterventions for stent reobstruction, migration, or stent fracture (3.2% uncovered group vs 20.7% covered group, P = .0490). The uncovered group had 2 major late complications: bleeding and perforation. All 60 patients died, with a median survival time of 51 days and 62 days, respectively.
Small-sized, single-center, retrospective study.
In palliation for malignant GOO, covered stents were associated with a more frequent need for reintervention than uncovered stents, despite similar outcomes and complications. These results require confirmation in a larger randomized comparison.
自膨式金属支架(SEMS)广泛用于缓解恶性胃出口梗阻(GOO)。然而,其使用的一个常见并发症是肿瘤向内生长或增生导致的支架阻塞。覆膜SEMS旨在预防这些问题。
我们比较了未覆膜和覆膜SEMS在GOO患者中的性能。
一项单中心回顾性研究。
一家三级转诊中心。
60例有症状的恶性GOO患者。
所有患者通过导丝置入法接受未覆膜或覆膜编织镍钛诺支架。
比较未覆膜和覆膜支架的临床结局、并发症及再次干预率。
31例患者(平均[±标准误]年龄72.2±2.1岁;16例男性)接受未覆膜SEMS,29例(平均[±标准误]年龄70.6±1.7岁;17例男性)接受覆膜SEMS。两组技术成功率均为100%。临床成功率无差异(未覆膜组90.3% vs覆膜组86.2%)。关于早期并发症(<1周),每组各有1例因支架覆盖乳头导致的轻度胰腺炎病例。晚期并发症包括再阻塞、移位、出血、支架断裂和穿孔。两组再阻塞发生率无差异(未覆膜组3.2% vs覆膜组10.3%)。移位情况无差异(未覆膜组0% vs覆膜组6.9%)。未覆膜组因支架再阻塞、移位或支架断裂需要再次干预的频率较低(未覆膜组3.2% vs覆膜组20.7%,P = 0.0490)。未覆膜组有2例主要晚期并发症:出血和穿孔。所有60例患者均死亡,中位生存时间分别为51天和62天。
小型、单中心、回顾性研究。
在缓解恶性GOO方面,尽管结局和并发症相似,但覆膜支架比未覆膜支架更频繁地需要再次干预。这些结果需要在更大规模的随机对照研究中得到证实。